The Hypertension Optimal Treatment trial - Aggressive blood pressure lowering is safe, but benefit is still hard to prove

被引:2
|
作者
Vidt, DG [1 ]
Pohl, MA [1 ]
机构
[1] Cleveland Clin Fdn, Dept Nephrol Hypertens, Cleveland, OH 44195 USA
关键词
D O I
10.3949/ccjm.66.2.105
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In the Hypertension Optimal Treatment (HOT) study, hypertensive patients who were randomly assigned to undergo antihypertensive treatment to achieve a goal diastolic blood pressure of 80 mm Hg or lower did not experience fewer cardiovascular events than did patients who received treatment with goal pressures of 85 or 90 mm Hg. Such aggressive antihypertensive treatment was safe and well tolerated, and did result in fewer cardiovascular events in the subset of patients with diabetes. All patients were randomly assigned to take aspirin 75 mg/day or placebo, and patients in the aspirin group had a 15% lower rate of major cardiovascular events and myocardial infarctions than did patients who received placebo. This finding establishes the efficacy of aspirin in preventing strokes and myocardial infarctions in hypertensive patients.
引用
收藏
页码:105 / 111
页数:7
相关论文
共 50 条
  • [31] Current prescription of blood pressure lowering drugs and adherence to treatment in Russian outpatients with arterial hypertension
    Pogosova, N.
    Oganov, R. G.
    Koltunov, I. E.
    Sokolova, O. Y.
    Vigodin, V. A.
    [J]. EUROPEAN HEART JOURNAL, 2011, 32 : 106 - 106
  • [32] Future Treatment of Hypertension: Shifting the Focus from Blood Pressure Lowering to Arterial Stiffness Modulation?
    Henry Fok
    J Kennedy Cruickshank
    [J]. Current Hypertension Reports, 2015, 17
  • [33] Baseline and on-treatment serum bicarbonate, intensive blood pressure lowering, and mortality: the Systolic Blood Pressure Intervention Trial (SPRINT)
    Pareek, M.
    Byrne, C.
    Vaduganathan, M.
    Biering-Sorensen, T.
    Krogager, M. L.
    Kragholm, K. H.
    McCullough, M.
    Desai, N. R.
    Olsen, M. H.
    Bhatt, D. L.
    [J]. EUROPEAN HEART JOURNAL, 2020, 41 : 2731 - 2731
  • [34] Controversies in Hypertension I: The Optimal Assessment of Blood Pressure Load and Implications for Treatment
    Filippone, Edward J.
    Foy, Andrew J.
    Naccarelli, Gerald, V
    [J]. AMERICAN JOURNAL OF MEDICINE, 2022, 135 (09): : 1043 - 1050
  • [35] Health economics in the Hypertension Optimal Treatment (HOT) study:: costs and cost-effectiveness of intensive blood pressure lowering and low-dose aspirin in patients with hypertension
    Jönsson, B
    Hansson, L
    Stålhammar, NO
    [J]. JOURNAL OF INTERNAL MEDICINE, 2003, 253 (04) : 472 - 480
  • [36] Evaluating the Benefit of Intensive Blood Pressure Lowering Based on Individual Outcome Profile: Post-hoc Analysis of the Systolic Blood Pressure Intervention Trial (SPRINT)
    Shi, S.
    Gouskova, N.
    Wei, L.
    Kim, D. H.
    [J]. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2021, 69 : S85 - S86
  • [37] Effects of blood pressure and blood pressure lowering treatment within 24 hours in the third International Stroke Trial of thrombolytic treatment for acute ischemic stroke
    Berge, E.
    Cohen, G.
    Lindley, R.
    Sandercock, P.
    Wardlaw, J. M.
    Sandset, E. C.
    Whiteley, W.
    [J]. INTERNATIONAL JOURNAL OF STROKE, 2015, 10 : 79 - 79
  • [38] REPRODUCIBILITY OF AMBULATORY BLOOD-PRESSURE AND ASSESSING TREATMENT WITHDRAWAL IN HYPERTENSION TRIAL
    REEVES, RA
    MYERS, MG
    [J]. AMERICAN JOURNAL OF HYPERTENSION, 1993, 6 (06) : S229 - S232
  • [39] A randomized controlled trial on the blood pressure-lowering effect of amlodipine and nifedipine-GITS in sustained hypertension
    Huang, Qi-Fang
    Sheng, Chang-Sheng
    Li, Yan
    Dou, Yu
    Zheng, Mei-Sheng
    Zhu, Zhi-Ming
    Wang, Ji-Guang
    [J]. JOURNAL OF CLINICAL HYPERTENSION, 2019, 21 (05): : 648 - 657